29 results on '"Pfister Marc"'
Search Results
2. Characterizing Associations of QTc Interval with Nocturnal Glycemic Control in Children with Type 1 Diabetes
3. Exploratory Literature Meta‐Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds
4. Application of individualized bayesian urea kinetic modeling (IBUKM) to pediatric hemodialysis.: 119
5. Pooled Population PK Modeling for Dapagliflozin. in Patients with Type 2 Diabetes Mellitus: 70
6. APIXABAN DOSE SELECTION FOR DVT PREVENTION IN ELECTIVE TOTAL KNEE REPLACEMENT SURGERY USING EXPOSURE-CLINICAL OUTCOME MODELING.: 75
7. TRIAL SIMULATION-BASED OPTIMAL SAMPLING DESIGNS FOR APIXABAN PHASE III STUDIES: 74
8. Eiposurc-Efficacy Outcome Modeling far Danagliflozin, An Orally Selective SGLT2 Inhibitor, In Patients With Type 2 Diabetes Mellitus: 69
9. Modeling and Simulation of Abatacept Exposure and Interleukin-6 Response in Support of Recommended Doses for Rheumatoid Arthritis
10. Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240
11. Age‐Dependent Changes of Kidney Injury Biomarkers in Pediatrics
12. Characterization of Maternal and Neonatal Pharmacokinetic Behavior of Ceftazidime
13. Facilitate Treatment Adjustment After Overdosing: Another Step Toward 21st-Century Medicine
14. Exploratory Literature Meta‐Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds
15. Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy
16. Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates
17. Novel Dialysis Modalities: Do We Need New Metrics to Optimize Treatment?
18. A Pharmacometric Approach to Quantify the Impact of Chronic Kidney Disease and Hemodialysis on Systemic Drug Exposure: Application to Saxagliptin
19. Design, Conduct, Analysis, and Interpretation of Clinical Studies in Patients With Impaired Kidney Function
20. Optimizing Drug Development and Use in Patients With Kidney Disease: Opportunities, Innovations, and Challenges
21. Optimizing Drug Development and Use in Patients With Kidney Disease
22. Defining the Future of Pharmacometrics: The American Society of Pharmacometrics
23. Model-Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry
24. Fostering Culture and Optimizing Organizational Structure for Implementing Model-Based Drug Development
25. The Emerging Scientific Discipline of Pharmacometrics
26. ACoP: The Tools, Carpenters, and Architects Building the Discipline of Pharmacometrics
27. Model‐Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development
28. Synergy Between Scientific Advancement and Technological Innovation, Illustrated by a Mechanism-Based Model Characterizing Sodium-Glucose Cotransporter-2 Inhibition
29. Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.